Please login to the form below

Not currently logged in
Email:
Password:

Parexel strengthens clinical leadership

Accenture MD Roland Andersson and Grunenthal’s Thomas Senderovitz join CRO

Parexel roland_andersson Parexel has named two new senior VPs within its clinical research services unit.

Dr Roland Andersson (pictured) joins the contract research organisation (CRO) from consultancy Accenture where he was managing director, while Dr Thomas Senderovitz joins from German pharma company Grunenthal, where he was executive VP of global compound development.

At Parexel the two new recruits will be involved in developing and implementing its global corporate objectives backed by a broad experience of the life sciences industry.

Dr Andersson's specific responsibilities include managing client relationships for phase II and phase III programmes on a global basis.

This follows on from his role at Accenture where he oversaw technology, consulting and business services for leading pharma and biotech companies. At Accenture, he was vital in the creation of TransCelerate BioPharma, an industry group that aligns companies to address common drug development problems

Dr Senderovitz will have responsibility for the management of Parexel's early phase and clinical logistics business units, as well as the global medical services function.

His past experience at Grunenthal includes providing strategic development and project oversight for all clinical development functions, including early clinical development, late stage clinical development, global clinical operations and global biometrics.

Prior to joining Grunenthal Dr Senderovitz served as VP of global exploratory development at UCB and VP of clinical R&D at Ferring Pharmaceuticals.

9th April 2014

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics